Category Archives: Indian Patent Law

“Indian CSO letter to the DPIIT on the proposed amendment to the Patent Rules”

20th May, 2019   New Delhi 16 May 2019 To Shri Ramesh Abhishek Secretary, Department for Promotion of Industry and Internal Trade, Ministry of Commerce & Industry, Room No.157 Udyog Bhawan, New Delhi Telephone : 2306 1815, 2306 1667, 23061598(F) … Continue reading

Posted in Fast track patent examination, Indian Patent Law, Patent examination system, Sec 3 (d) | Leave a comment

People living with hepatitis C and HIV challenge evergreening patents on lifesaving hepatitis C drugs in India

New Delhi, 10 July 2018: Delhi Network of Positive People (DNP+) has filed today two patent oppositions before the Indian patent office, challenging additional patent claims by US pharmaceutical corporation-Gilead Sciences for the hepatitis C medicines sofosbuvir and velpatasvir. These … Continue reading

Posted in Drug prices, Hepatitis C, Indian Patent Law, Patent, Patent Opposition, Sec 3 (d) | Tagged , | Leave a comment

Five years after the Indian Supreme Court’s novartis verdict

Source: Intellectual Property Watch | May 21, 2018 On 1 April 2013, in a packed room inside India’s Supreme Court, a magnificent building in Indo-British architectural style, two judges delivered a verdict that impacted the national and global conversation about … Continue reading

Posted in Novartis Case, Sec 3 (d) | Leave a comment

Weed out evergreen patents

Source: Live Law | May 27, 2018 A recently published report “Pharmaceutical Patent Grants in India: How our safeguards against evergreening have failed and why the system must be reformed“, by Dr. Feroz Ali, Dr. Sudarsan Rajagopal, Dr. Venkata S. … Continue reading

Posted in Evergreening, Patents, Sec 3 (d) | Leave a comment

Why the US and pharmaceutical giants want a provision in India’s patent law revoked

Source: Scroll.in | May 02, 2018 India’s patent laws are under attack again. This time, too, the target is a provision not commonly found in patent laws elsewhere. This rule requires patent holders to disclose whether they are working their … Continue reading

Posted in Generics, Indian Patent Law, IPR, Patents | Leave a comment

Report on Pharmaceutical Patents in India – How our safeguards against evergreening have failed, and why the system must be reformed

  The recent report on “Pharmaceutical Patent Grants in India How our safeguards against evergreening have failed, and why the system must be reformed” shows immense irregularities in grant of patents in the country. Over the past decades India’s patent system has … Continue reading

Posted in Evergreening, Fix the patent law, India, Indian Patent Law, Indian Patent Office | Leave a comment

Rampant evergreening in Indian pharma industry

Source: live mint | April 27, 2018 Pharmaceutical companies commonly used legal argument, as opposed to demonstrating proof of therapeutic efficacy, to overcome anti-evergreening objections India has been at the forefront of developing an alternative model of patent law which … Continue reading

Posted in Indian Patent Law, Indian Patent Office, Sec 3 (d), Uncategorized | Leave a comment